Gossamer Bio Inc. Common Stock (GOSS)
Stock · NASDAQ · Health Care
$8.7as of 10/16/2026
Price chart
Active signals
GOSS Signal Track Record
How signals performed across all stocks →What GOSS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +5.6% | 55% | July 14, 2026 |
| Bollinger Band Breakout | 27 | 0.0% | 48% | September 11, 2026 |
| Bollinger Band Breakdown | 19 | -11.8% | 26% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -1.6% | 44% | April 24, 2025 |
| Any 20-session window (baseline) | -2.5% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial f…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 161
- Website
- www.gossamerbio.com/
Fundamentals
- 1-day range
- $8.73$9.18
- Market cap
- $87.21M
- P/E (trailing)
- —
- P/E (forward)
- -0.57
- EPS (trailing)
- $-0.56
- Dividend yield
- —
- Beta
- 2.28
- Avg. volume
- 376.9K
How Gossamer Bio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Gossamer Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GOSSGossamer Bio Inc. Common Stock$8.77▼ 1.35%Market cap $87.21MP/E —$8.77$309.6
- MAIAMAIA Biotechnology Inc. Common Stock$1.1▼ 1.79%Market cap $86.34MP/E —$0.87$3.19
- BMEABiomea Fusion Inc. Common Stock$0.869▲ 3.95%Market cap $90.37MP/E —$0.800501$2.24
- NTHINeOnc Technologies Holdings Inc. Common Stock$2.7▼ 1.82%Market cap $90.77MP/E —$2.5$12
- LFVNLifevantage Corporation Common Stock (Delaware)$6▲ 0.00%Market cap $83.01MP/E 14.40$3.9$11.71
- ATHEAlterity Therapeutics Limited American Depositary Shares$2.62▼ 3.68%Market cap $82.65MP/E —$0.01$0.785
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GOSS Gossamer Bio Inc. Common Stock | $87.21M | — | $8.77 | ▼ 1.35% | $8.77$309.6 |
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.1 | ▼ 1.79% | $0.87$3.19 |
| BMEA Biomea Fusion Inc. Common Stock | $90.37M | — | $0.869 | ▲ 3.95% | $0.800501$2.24 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $2.7 | ▼ 1.82% | $2.5$12 |
| LFVN Lifevantage Corporation Common Stock (Delaware) | $83.01M | 14.40 | $6 | ▲ 0.00% | $3.9$11.71 |
| ATHE Alterity Therapeutics Limited American Depositary Shares | $82.65M | — | $2.62 | ▼ 3.68% | $0.01$0.785 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDAYahoo · 10/1/2026
- Curious about the stocks that are showing activity after the closing bell on Friday?ChartMill · 9/25/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/25/2026
- Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial HypertensionYahoo · 9/23/2026
- Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial HypertensionBenzinga · 9/23/2026
- HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $90Benzinga · 9/21/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/18/2026
- Gossamer Bio Appoints Greg Ciongoli to Board of DirectorsYahoo · 9/16/2026
Insider Activity
Insider Actions →- Milligan Sandra · September 23, 2026 · Grant10.0K
- Gregory Austin Ciongoli · September 23, 2026 · Grant30.0K
- Drynan Skye · September 23, 2026 · Grant10.0K
- Nathan Steven D · September 23, 2026 · Grant10.0K
- Quisel John D · September 23, 2026 · Grant10.0K
- Daniel Thomas O · September 23, 2026 · Grant10.0K
- Cox Russell J. · September 23, 2026 · Grant10.0K
- Peterson Caryn · August 24, 2026 · Grant5.80M
- Bryan Giraudo · August 24, 2026 · Grant5.80M
- Bryan Giraudo · August 24, 2026 · Grant25 @ $1,000
- Christian Waage · August 24, 2026 · Grant2.90M
- Faheem Hasnain · August 24, 2026 · Grant5.80M
- Faheem Hasnain · August 24, 2026 · Grant166 @ $1,000
- Smith Robert Paul JR · August 24, 2026 · Grant5.80M
- Nathan Steven D · June 4, 2026 · Grant115.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 166.63M
- Total value held
- $52.29M
- Institutional holders
- 186
- Unknown16.83M
- Unknown10.13M
- Unknown9.39M
- Unknown8.06M
- Unknown7.75M
- Unknown7.47M
- Unknown7.22M
- Unknown5.92M
- Unknown5.28M
- Unknown5.21M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension
Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension. Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.